Neurocrine officer plans sale of 2,154 shares

NEUROCRINE BIOSCIENCES, INC.

Available on EDGAR 09/09/2026 - 04:20 PM EDT Accepted by SEC EDGAR 09/09/2026 - 04:19 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES, INC. (NBIX) received a Rule 144 notice that officer Eric Benevich plans to sell up to 2,154 shares of common stock. The shares are expected to be sold on or about September 9, 2026 on NASDAQ through Morgan Stanley Smith Barney LLC after a cash exercise of stock options.

Key Figures

Shares to be sold under Rule 144: 2,154 shares Expected sale date: September 9, 2026 Form type: Rule 144 notice of proposed sale

3 metrics

Shares to be sold under Rule 144 2,154 shares Planned sale of Neurocrine Biosciences, Inc. common stock by an officer

Expected sale date September 9, 2026 Planned disposition date for the 2,154 shares

Form type Rule 144 notice of proposed sale Notice filed for planned sale of restricted/controlled securities

Key Terms

Rule 144, Exercise of Stock Options, Executive Financial Services

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Common | 09/09/2026 | Exercise of Stock Options | Issuer"

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Rule 144 filing disclose for NBIX?

It discloses that officer Eric Benevich intends to sell up to 2,154 shares of Neurocrine Biosciences, Inc. common stock under Rule 144, with sales expected around September 9, 2026 after a cash exercise of stock options.

How many NBIX shares are planned for sale in this Rule 144 notice?

The notice reports a planned sale of up to 2,154 shares of Neurocrine Biosciences, Inc. common stock. This figure represents the amount covered by the Rule 144 filing for proposed disposition.

When are the NBIX shares expected to be sold under this Rule 144 filing?

The filing lists an expected sale date of September 9, 2026 for the 2,154 shares of Neurocrine Biosciences, Inc. common stock to be sold under Rule 144.

What is the source of the NBIX shares being sold in this filing?

The shares are to be issued through an exercise of stock options on September 9, 2026, with the exercise paid in cash, and then sold under Rule 144.

Which broker is named for the NBIX Rule 144 sale?

The planned sale of 2,154 shares of Neurocrine Biosciences, Inc. common stock is to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services, with trading on NASDAQ as stated in the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001643653
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	NEUROCRINE BIOSCIENCES, INC.
SEC File Number	000-22705
Address of Issuer	6027 Edgewood Bend Court San Diego CALIFORNIA 92130
Phone	8586177600
Name of Person for Whose Account the Securities are To Be Sold	ERIC BENEVICH
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2154	334150.02	101649181	09/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/09/2026	Exercise of Stock Options	Issuer			2154	09/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Eric Benevich
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)